News | October 30, 2023
Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
PFA technology is only marketed in Europe, and yet, it has been dominating the electrophysiology market by storm
Eni will guarantee Dompé researchers access to its laboratories, support from the company's specialized staff, and use of its HPC5 supercomputer
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Subscribe To Our Newsletter & Stay Updated
